Chengdu Kanghua Biological Products (300841) — Working Capital to Net Assets Ratio
Chengdu Kanghua Biological Products (300841) has a Working Capital to Net Assets ratio of 57.1% as of September 2025. Working capital of CN¥2.00 Billion (current assets of CN¥2.42 Billion minus current liabilities of CN¥412.88 Million) is measured against net assets of CN¥3.51 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See how leveraged is Chengdu Kanghua Biological Products's balance sheet to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Chengdu Kanghua Biological Products Working Capital to Net Assets (2015–2024)
This chart shows how Chengdu Kanghua Biological Products's Working Capital to Net Assets ratio has evolved across 10 annual periods from 2015 to 2024. As of September 2025, the ratio stands at 57.1%, reflecting working capital of CN¥2.00 Billion against net assets of CN¥3.51 Billion CNY. Check Chengdu Kanghua Biological Products (300841) tangible net worth to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Chengdu Kanghua Biological Products (2015–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Chengdu Kanghua Biological Products from 2015 to 2024, covering 10 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see market value of Chengdu Kanghua Biological Products.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 55.7% | CN¥1.92 Billion | CN¥3.45 Billion | CN¥2.49 Billion | CN¥566.37 Million | ▼ -0.5 pp |
| 2023 | 56.2% | CN¥1.98 Billion | CN¥3.51 Billion | CN¥2.66 Billion | CN¥681.72 Million | ▲ +6.4 pp |
| 2022 | 49.9% | CN¥1.53 Billion | CN¥3.08 Billion | CN¥2.15 Billion | CN¥611.71 Million | ▼ -10.2 pp |
| 2021 | 60.1% | CN¥1.60 Billion | CN¥2.67 Billion | CN¥1.94 Billion | CN¥338.94 Million | ▼ -21.4 pp |
| 2020 | 81.5% | CN¥1.61 Billion | CN¥1.97 Billion | CN¥1.78 Billion | CN¥170.33 Million | ▲ +0.7 pp |
| 2019 | 80.8% | CN¥464.24 Million | CN¥574.65 Million | CN¥577.31 Million | CN¥113.07 Million | ▲ +5.9 pp |
| 2018 | 74.9% | CN¥275.54 Million | CN¥367.70 Million | CN¥392.34 Million | CN¥116.81 Million | ▲ +9.3 pp |
| 2017 | 65.6% | CN¥123.64 Million | CN¥188.37 Million | CN¥209.20 Million | CN¥85.56 Million | ▼ -112.5 pp |
| 2016 | 178.2% | CN¥-171.42 Million | CN¥-96.21 Million | CN¥125.48 Million | CN¥296.90 Million | ▼ -1.9 pp |
| 2015 | 180.1% | CN¥-185.26 Million | CN¥-102.87 Million | CN¥87.17 Million | CN¥272.43 Million | — |